Acute Lymphoblastic Leukemia — Trials

Acute Lymphoblastic Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

2,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 546
Recruiting: 330
Ph III recruiting: 26
Growth YoY: −10%
Industry share: 13%
Top sponsor: City of Hope Medical Center
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (268)

clinicaltrialsPublishedShowing 1–50 of 732 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03739814	Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia	recruiting	Phase 2	84	National Cancer Institute (NCI)NIH	2	Sep 29, 2026	clinicaltrials
NCT06738368	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia	suspended	Phase 2	30	University of Washington